The international Unity study for antivirals against mpox is a blueprint for future epidemics
Nat Med
.
2023 Aug;29(8):1894-1895.
doi: 10.1038/s41591-023-02393-6.
Authors
Erica Telford
1
,
Beatriz Grinsztejn
2
,
Inge Christoffer Olsen
3
,
Nicolas Pulik
1
,
France Mentré
4
5
,
Skerdi Haviari
4
,
Maxime Hentzien
6
,
Olivier Ségéral
6
,
Miquel B Ekkelenkamp
7
,
Dimie Ogoina
8
,
Nathalie Strub-Wourgaft
9
,
Alpha Diallo
1
,
Yazdan Yazdanpanah
1
5
10
,
Alexandra Calmy
11
Affiliations
1
ANRS|Emerging Infectious Diseases/Inserm, Paris, France.
2
Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
3
Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.
4
Département d'Épidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, AP-HP, Paris, France.
5
Université de Paris, IAME, Inserm, Paris, France.
6
HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland.
7
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
8
Infectious Diseases Unit, Department of Internal Medicine, Niger Delta University/Niger Delta University Teaching Hospital, Bayelsa, Nigeria.
9
PANTHER, Paris, France.
10
Service de Maladies Infectieuses et Tropicales, Hôpital Bichat, AP-HP, Paris, France.
11
HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland.
[email protected]
.
PMID:
37391664
DOI:
10.1038/s41591-023-02393-6
No abstract available
Publication types
Letter
MeSH terms
Antiviral Agents* / therapeutic use
Humans
Mpox, Monkeypox*
Substances
Antiviral Agents